Alzamend Neuro Inc Stock Price, News & Analysis

BitNile Holdings Achieves 120% Revenue Growth

BitNile Holdings (NILE) reported a significant revenue increase of 120% to $52.4 million for the year ended December 31, 2021, up from $23.9 million in 2020. The company ended the year with total assets of $490 million and experienced a net loss reduction to $24.2 million. Key revenue growth drivers included lending and trading activities ($16.9 million) and cryptocurrency mining ($3.5 million).

Alzamend Neuro, Inc. (NASDAQ: ALZN) announced a partnership with Altasciences and iResearch Atlanta to conduct a Phase IIA multiple ascending dose study for AL001, a novel treatment for Alzheimer’s Disease. Enrollment is set to begin in May 2022. The Phase I study demonstrated that AL001 is bioequivalent to marketed lithium carbonate, indicating its potential safety and efficacy. This advancement may reduce the need for extensive Phase II and III studies. Alzamend aims to improve treatment options for Alzheimer's and related conditions.

Alzamend Neuro, Inc. (Nasdaq: ALZN) has appointed Dr. Terri Hunter to its Scientific Advisory Board. Dr. Hunter, a Technology Transfer Specialist with experience managing patents for Alzamend’s candidates AL001 and AL002, expresses enthusiasm for the company's progress in clinical trials. AL001 is a novel lithium-delivery system intended for Alzheimer’s treatment, aiming to provide benefits without current toxicities. Alzamend plans to begin a Phase 2 study involving Alzheimer's patients and submit an investigational new drug application for AL002 in Q2 2022.

Alzamend Neuro has confirmed positive results from its Phase 1 trial of AL001, a lithium-delivery system intended for Alzheimer's treatment. The data demonstrate that AL001 is bioequivalent to marketed lithium carbonate, with a significantly lower dosage and similar plasma concentration curves. No serious adverse events occurred, indicating a favorable safety profile. With over 40 million Americans affected by related conditions, AL001 may reduce the need for lithium monitoring and provide a safer alternative. The company plans to initiate a Phase 2 study in Alzheimer's patients soon.

Alzamend Neuro has reported positive topline results from its Phase 1 clinical trial for AL001, a lithium delivery system aimed at treating Alzheimer's disease. The trial demonstrated that AL001 is bioequivalent to marketed lithium carbonate, suggesting the potential for effective treatment at lower doses. AL001's safety profile is benign with no significant adverse effects noted. The company plans to initiate a Phase 2 trial and pursue regulatory applications for several psychiatric disorders within the year, addressing a critical public health need.

Alzamend Neuro, Inc. (Nasdaq: ALZN) recently announced that the topline data for its Phase 1 clinical trial of AL001, aimed at treating dementia related to Alzheimer’s, will be released in mid- to late-December 2021. The company aims to utilize these results to swiftly transition into a Phase 2 study in early 2022. In addition, the FDA has agreed to a combined Phase 1/2 clinical study for AL002, a cell-based vaccine aimed at Alzheimer's, with an IND submission planned for Q2 2022. The positive FDA feedback is a significant step for Alzamend in its development of innovative therapies for neurodegenerative diseases.

Ault Global Holdings (NYSE American: DPW) reported significant financial results for the nine months ending September 30, 2021. Revenue increased by 167% to $44.6 million, bolstered by lending and trading activities, contributing $19.6 million. However, Q3 saw a revenue decline of $36.5 million, totaling negative $30.8 million, mainly due to unrealized losses in investments, particularly a $33.4 million loss from Alzamend Neuro (Nasdaq: ALZN). Despite a net income of $1.3 million for nine months, Q3 net loss was $42.9 million.

Alzamend Neuro has received FDA approval to proceed with a combined Phase 1 and 2 clinical trial for its Alzheimer’s treatment AL002. The therapy aims to utilize a mutant-peptide sensitized cell to enhance the immune system's ability to combat Alzheimer’s by reducing beta-amyloid plaques. Alzamend intends to file its IND application by the end of November 2021 and begin the clinical trial in early 2022, based on positive preclinical results and feedback from the FDA.